Advanced searches left 3/3

Liver Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

Patient-Centered Liver Cancer Prevention in the Houston Community Screening for Predictors of Fibrosis and Cirrhosis

"To determine the sensitivity of the updated Center for Disease Control hepatitis survey in identifying chronic hepatitis B virus among HOPE clinic patients. " To determine the sensitivity of the updated CDC hepatitis survey in identifying persistent hepatitis C virus infection among HOPE clinic patients, it is best to determine the sensitivity of the updated CDC hepatitis survey. In detecting fibrosis among HOPE clinic patients with metabolic disorders, we need to know the sensitivity of fibrosis serum biomarkers, non-alcoholic fatty liver disease fibrosis score, fibrosis-4 index, and fatty liver disease fibrosis index can be determined. The Alcohol Use Disorder Identification Test Alcohol Consumption Test Alcohol Consumption was used to determine fibrosis among HOPE clinic patients in order to determine fibrosis. On the AUDIT-C. V. To determine the specificity and accuracy of each of these risk factor screening techniques in HOPE clinic patients, one of the AUDIT-10 questionnaire in identifying fibrosis among Hope Clinic patients who scored >=4 for men or >= 3 for women.

Source link: https://clinicaltrials.gov/ct2/show/NCT04785534


Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

"Primary Objective: This prospective pilot study's main aim is to: determine the suitability and reproducibility of 3D contrast enhanced ultrasound imaging in liver cancer patients undergoing stereotactical Radiotherapy, and determine whether there are treatment-induced changes in imaging metrics derived from 3D contrast enhanced ultrasound. Evaluate the feasibility of contrast-enhanced ultrasound-to-CT fusion by assisting three-dimensional perfusion ultrasound guidance with optical and electromagnetic tracking of the ultrasound probe into liver cancer patients who will undergo CT for treatment planning and/or response evaluation. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT02424955


A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)

"Background: Primary liver cancer is the second most common cause of cancer-related deaths worldwide, with two main histological subtypes, i. e. , hepatocellular carcinoma and cholangiocarcinoma, in which diagnoses and treatment decisions are solely based on their baseline clinical findings. " Despite major efforts to improve diagnosis and the emergence of new treatment modalities, the improvement of PLC patient longevity is negligible. Immunotherapy is a promising new step forward in PLC therapy. Programmed cell death protein-1 ligand 1 and cytotoxic T lymphocyte antigen 4 are two examples of anti-tumor T cell function, which inhibit anti-tumor T cell function. Currently, several trials are ongoing to see the effect of immune checkpoint inhibitors as single agents or in combination with targeted therapy on PLC formation and outcome. Initial results from PLC's Phase I/II clinical trials are encouraging, but PLC's preliminary findings suggest that only those patients respond to such treatment regimens, while others do not or suffer from resistance/relapse. Hence, we plan to collect PLC patient specimens and clinical data from those undergoing immunotherapy at the National Institute Hospital Center and a handful of academic clinic centers in order to identify predictors of response or resistance to immunotherapy and acquired resistance to immunotherapy. Patients with planned or a history of at least one dose of immunotherapy for HCC or CCA. Patient outcome data can also be obtained from national death index data. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT04145141


A Pilot Social Network and Support Intervention to Improve Kidney and Liver Cancer Treatment Among Hispanics in Arizona

In n=100, the aim of this 6-month patient navigator's telephone-based social service project was to determine 1 feasibility of a full-scale intervention in Hispanic kidney and liver cancer patients and 2 the impact of intervention on timely treatment preparation and adherence to follow-up care. " In addition, the investigators will investigate the effects of social care intervention on timely treatment initiation after diagnosis. Patients with kidney and liver cancer start treatment within three months after diagnosis and continue to receive follow-up care. Kidney cancer patients receive an imaging exam for other reasons, including coincidental findings of a kidney mass. Patients will be screened and follow-up imaging examination or scheduled appointments with hepatologists or urologists, depending on whether patients plan and arrive for follow-up imaging assessment or scheduled appointments with hepatologists or urologists, and how long the delay in follow-up care will be determined. This series of intervention education resources will be used as an evidence-based guide for simple reference, including frequently asked questions, information on how to contact health care professionals when patients have symptoms, tips for dealing with health care professionals, family members, and friends, as well as tips on lifestyle modification i. e. The results of this pilot project will be used to develop a larger, adequately funded controlled trial to more thoroughly investigate the effects of incorporating social media platforms into healthcare in order to minimize the adverse effects of social deprivation and treatment timeliness and compliance with recommended therapy. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05418387


Pilot Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer

"Evaluation and tolerability of an autologous dendritic cell vaccine administered intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy. " To determine the overall response rate in patients with liver cancer treated with high-dose conformal EBRT and autologous DC vaccine injection, followed by autologous DC vaccine injection. To determine the clinical benefit rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection, we'll find out later this year. To determine the time of response in patients with liver cancer treated with high-dose conformal EBRT and autologous DC vaccine injection, followed by autologous DC vaccine injection. To determine overall survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection, according to the authors. On day 1 of cycles 2-8, patients then receive autologous dendritic cells intratumorally, and pneumococcal 13-valent conjugate vaccine intramuscularly on day 1 of cycles 2-4. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT03942328


A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination With Brivanib Alaninate (ZL-2301) in Patients With Advanced Liver Cancer

"This research includes two parts: Phase I is a dose escalation study to determine the recommended Phase II Dose of MGD013 monotherapy and one of MGD013 in combination with Brivanib Alanine in patients with advanced liver cancer.

Source link: https://clinicaltrials.gov/ct2/show/NCT04212221


Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms

"Methods to increase treatment volumes could be helpful in potentially raising the risks of thermal ablation or the number of patients benefiting from local ablation. " Patients of greater than 18 years of age with pathologically confirmed primary or metastatic hepatic neoplasms are expected to have minimal ECOG performance status of less than six months, with a life expectancy of more than six months patients with a history of chemotherapy, radiation therapy, liver disease, or biologic therapy must have been waiting for at least 14 days before starting research trials. Patients may be treated with a second thermal ablation treatment ALONE by the investigator if it is considered safe for the patient by the investigator. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT01862718

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions